Wayne, PA, United States of America

Yaowei Zhu

This inventor holds 1 USPTO granted patent and 6 published patent applications. Top assignee: Momenta Pharmaceuticals, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yaowei Zhu. Retrieved from https://idiyas.com/inventor/yaowei-zhu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yaowei Zhu and His Patent Work

Introduction

Yaowei Zhu is an inventor associated with Wayne, Pennsylvania, and Momenta Pharmaceuticals, Inc. His patent work includes an invention concerning anti-FcRn antibodies and potential treatment for myasthenia gravis.

Latest Patents

Zhu is credited with 1 patent: “Anti-FcRn Antibodies and Methods for Treating Myasthenia Gravis.” The patent describes antibodies targeting the neonatal Fc receptor (FcRn) and methods related to treating myasthenia gravis.

Career Highlights

Zhu’s listed patent connects his work with antibody-based therapeutic research at Momenta Pharmaceuticals, Inc. The invention focuses on a potential treatment approach for an autoimmune neuromuscular disorder.

Collaborations

The provided information lists Shawn Black and Jocelyn H. Leu as Zhu’s coworkers. Their names are associated with his professional context, though the supplied details do not specify their roles in the patent.

Conclusion

Yaowei Zhu’s patent record highlights work on anti-FcRn antibodies and methods for treating myasthenia gravis, reflecting a contribution to therapeutic innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…